Vered Stearns
#160,441
Most Influential Person Now
Researcher
Vered Stearns's AcademicInfluence.com Rankings
Vered Stearnsmedical Degrees
Medical
#3218
World Rank
#3676
Historical Rank
Oncology
#222
World Rank
#230
Historical Rank
Vered Stearnsphilosophy Degrees
Philosophy
#9231
World Rank
#12760
Historical Rank
Logic
#6219
World Rank
#7715
Historical Rank
Download Badge
Medical Philosophy
Vered Stearns's Degrees
- Doctorate Medicine Tel Aviv University
- PhD Oncology Johns Hopkins University
Why Is Vered Stearns Influential?
(Suggest an Edit or Addition)Vered Stearns's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. (2005) (932)
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. (2003) (837)
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) (671)
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. (2006) (671)
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. (2014) (612)
- Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. (2012) (548)
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013) (539)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (524)
- Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. (2003) (497)
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment (2006) (468)
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
- Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer (2014) (328)
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. (2015) (320)
- When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. (2001) (318)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. (2017) (311)
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood (2012) (305)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (294)
- Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. (2012) (290)
- CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. (2012) (256)
- A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. (2000) (240)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. (2016) (228)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. (2019) (227)
- Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis (2001) (219)
- Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. (2005) (214)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. (2013) (211)
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. (2010) (199)
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer (2012) (197)
- Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors (2008) (196)
- Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. (2008) (182)
- Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI (2007) (182)
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer (2002) (181)
- Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. (2009) (161)
- ESO-ESMO 4rd International Consensus Guidelines for Breast Cancer in Young Women (BCY4). (2020) (149)
- Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate (2015) (122)
- A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. (2003) (121)
- New prognostic factors for breast cancer recurrence. (2001) (120)
- Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients (2010) (112)
- Epigenetics as a Therapeutic Target in Breast Cancer (2012) (109)
- Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. (2008) (107)
- Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. (2002) (105)
- Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management (2011) (104)
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study (2016) (99)
- Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. (2008) (95)
- DNA methylation-related vitamin D receptor insensitivity in breast cancer (2010) (90)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. (2019) (89)
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age (2011) (89)
- Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. (2012) (88)
- Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. (2012) (86)
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients (2009) (84)
- Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. (2008) (83)
- Circulating tumor markers in breast cancer: Accepted utilities and novel prospects (2004) (80)
- Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants (2006) (79)
- Epigenetic Regulation as a New Target for Breast Cancer Therapy (2007) (77)
- A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors (2013) (76)
- Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy (2014) (76)
- Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo (2012) (74)
- Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer (2011) (72)
- In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. (2010) (71)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. (2016) (70)
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort (2009) (69)
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
- Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? (2008) (66)
- Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design (2017) (66)
- CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer? (2018) (64)
- CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance (2010) (63)
- Activation of diverse signaling pathways by oncogenic PIK3CA mutations (2014) (62)
- Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer (2011) (61)
- Does tamoxifen cause cancer in humans? (1998) (61)
- Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? (2009) (59)
- Hot flushes (2002) (58)
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer (2015) (58)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors (2007) (58)
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. (2017) (58)
- Symptoms, supportive care needs, and function in cancer patients: how are they related? (2008) (58)
- Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response (2010) (56)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases (2014) (55)
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update (2022) (55)
- Modeling hot flushes and quality of life in breast cancer survivors (2011) (54)
- Pharmacogenetics in the treatment of breast cancer (2004) (54)
- Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30 (2010) (54)
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. (2008) (51)
- Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer (2016) (51)
- Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. (2016) (51)
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer (2013) (49)
- Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer (2016) (49)
- Pharmacogenetics of endocrine therapy for breast cancer. (2011) (49)
- Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. (2006) (48)
- Abstract S1-7: Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. (2010) (48)
- Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer (2011) (48)
- Patient‐reported outcomes in women with breast cancer enrolled in a dual‐center, double‐blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor‐induced musculoskeletal symptoms (2014) (48)
- Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. (2016) (47)
- Centrally active nonhormonal hot flash therapies. (2005) (46)
- Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. (2012) (45)
- Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. (2014) (45)
- The role of c-erbB-2 as a predictive factor in breast cancer (2001) (44)
- Pharmacogenomics of breast cancer therapy: an update. (2013) (44)
- Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways (2015) (43)
- Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications (2004) (43)
- Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. (2010) (42)
- A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography (2010) (41)
- Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. (2015) (41)
- Concordance of cancer patients’ function, symptoms, and supportive care needs (2009) (41)
- Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. (2014) (41)
- Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. (2019) (41)
- Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer (2018) (40)
- Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen (2008) (39)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. (2016) (38)
- Novel Biomarkers in the Continuum of Breast Cancer (2016) (38)
- A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? (2008) (37)
- Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study (2010) (36)
- Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. (2009) (36)
- Predictors of recovery of ovarian function during aromatase inhibitor therapy. (2013) (34)
- Serotonergic Agents as an Alternative to Hormonal Therapy for the Treatment of Menopausal Vasomotor Symptoms (2006) (33)
- TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. (2020) (33)
- Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. (2020) (33)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary. (2017) (33)
- TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (2011) (32)
- Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. (2006) (31)
- Increasing Physical Activity Amongst Overweight and Obese Cancer Survivors Using an Alexa-Based Intelligent Agent for Patient Coaching: Protocol for the Physical Activity by Technology Help (PATH) Trial (2018) (31)
- The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer (2016) (31)
- Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. (2009) (31)
- Clinical update: new treatments for hot flushes (2007) (31)
- Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects (2013) (30)
- Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer (2020) (30)
- TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. (2019) (29)
- Treatment strategies for hot flushes. (2009) (28)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT (2006) (28)
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole (2012) (27)
- Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. (2018) (27)
- Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer (2013) (27)
- Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors (2020) (26)
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover (2015) (25)
- New therapeutic approaches for hot flashes in women. (2003) (25)
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications (2010) (25)
- Current approaches for neoadjuvant chemotherapy in breast cancer. (2013) (25)
- Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy (2009) (24)
- Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (2014) (22)
- Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period (2020) (22)
- Can Hypnosis Reduce Hot Flashes in Breast Cancer Survivors? A Literature Review (2004) (22)
- Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions. (2015) (22)
- Treatment strategies for hot flushes (2009) (22)
- Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer (2016) (21)
- Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration (2009) (21)
- Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). (2012) (21)
- Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer* (2015) (20)
- The biology of hormone refractory breast and prostate cancer: An NCI workshop report (2009) (20)
- A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia (2004) (19)
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. (2006) (19)
- Cooling off hot flashes. (2002) (19)
- Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors (2012) (18)
- Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women (2004) (18)
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (2011) (18)
- Cancer support and resource needs among African American older adults (2012) (18)
- Sharing in care: engaging care partners in the care and communication of breast cancer patients (2019) (18)
- Lipophilic statins merit additional study for breast cancer chemoprevention. (2006) (17)
- Approach to menopausal symptoms in women with breast cancer (2002) (17)
- Use of Geriatric Assessment Tools in Selecting Therapies in Women Aged ≥70 Years With Hormone Receptor-Positive Early-Stage Breast Cancer: Preliminary Experience With a Quality Improvement Initiative. (2017) (17)
- Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis (2019) (17)
- CYP2D6 genotype and tamoxifen response (2005) (17)
- Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. (2015) (16)
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (2014) (16)
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy (2015) (16)
- A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
- A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
- A randomized intervention involving family to improve communication in breast cancer care (2021) (15)
- Statins and Breast Cancer: Future Directions in Chemoprevention (2013) (15)
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
- Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results (2010) (15)
- A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. (2014) (15)
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
- A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (2011) (15)
- Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins (2016) (15)
- Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. (2014) (15)
- Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials (2018) (15)
- Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy (2009) (14)
- Postmenopausal hormone receptor-positive advanced breast cancer. (2013) (13)
- Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis (2016) (13)
- A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial (2018) (13)
- Management of hormone receptor-positive, HER2-negative early breast cancer. (2020) (13)
- Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. (2010) (13)
- Expanded‐Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2‐Negative Advanced Breast Cancer (2018) (13)
- Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008 (2017) (12)
- A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity (2004) (12)
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
- Intraductal fulvestrant for Therapy of ERα-positive Ductal Carcinoma in Situ (DCIS) of the breast- a Preclinical Study. (2019) (11)
- Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. (2013) (11)
- High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer (2019) (11)
- TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. (2019) (11)
- Intraductal therapy for the prevention of breast cancer. (2010) (11)
- Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk (2018) (11)
- Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide (2020) (10)
- Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk (2016) (10)
- Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer (2021) (10)
- A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). (2010) (10)
- The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial (2020) (10)
- Management of hot flashes in breast cancer survivors and men with prostate cancer (2004) (10)
- Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States (2020) (10)
- Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. (2007) (10)
- Chemotherapeutic Strategies for advanced breast cancer. (2007) (10)
- Optimizing Vitamin D Concentrations for Breast Cancer Risk Reduction (2013) (9)
- Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. (2012) (9)
- Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer (2017) (9)
- Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR-/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program. (2019) (9)
- Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (2011) (9)
- Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844) (2021) (9)
- Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial. (2009) (9)
- Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. (2019) (8)
- Personalized Tamoxifen: A Step Closer but Miles To Go (2010) (8)
- Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. (2021) (8)
- Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors (2017) (8)
- A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities. (2010) (8)
- Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( 23 Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2012) (8)
- OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. (2011) (7)
- ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. (2016) (7)
- Considerations for the Use of Scalp Cooling Devices in Black Patients. (2020) (7)
- Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients (2017) (7)
- A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. (2009) (6)
- Effect of simvastatin on the pharmacokinetics of anastrozole (2016) (6)
- The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). (2018) (6)
- Dynamic Brain Activity Following Auricular Point Acupressure in Chemotherapy-Induced Neuropathy: A Pilot Longitudinal Functional Magnetic Resonance Imaging Study (2020) (6)
- Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer (2021) (6)
- RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer (2021) (6)
- Survivorship care visits in a high-risk population of breast cancer survivors (2018) (6)
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019) (5)
- TAILORing Adjuvant Systemic Therapy for Breast Cancer. (2018) (5)
- Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Breast Cancer: Update Summary of ASCO Cancer Care Ontario Guideline Endorsement. (2019) (5)
- Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy (2019) (5)
- Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment. (2022) (5)
- Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse. (2015) (5)
- Abstract S3-02: Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy (2013) (5)
- Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. (2021) (5)
- The relationship of single-strand breaks in DNA to breast cancer risk and to tissue concentrations of oestrogens (2017) (5)
- Adjuvant aromatase inhibitors and emerging quality-of-life considerations (2008) (5)
- Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover) (2021) (5)
- POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program on biomarkers in women with early-stage breast cancer. (2014) (5)
- Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. (2019) (5)
- Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors (2021) (5)
- Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008). (2012) (4)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). (2013) (4)
- The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife. (2004) (4)
- Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. (2009) (4)
- Abstract 5593: A combination of HDAC inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and low dose Doxorubicin causes regression of established xenografts of triple negative breast cancer (2010) (4)
- Abstract 54: Addressing Cardiovascular Health Using Artificial Intelligence: Randomized Clinical Trial to Increase Physical Activity in Cancer Survivors Using Intelligent Voice Assist (Amazon Alexa) for Patient Coaching (2020) (4)
- Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection (2015) (4)
- New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17. (2016) (4)
- A diet low in fat and high in vegetables, fruit, and fiber following breast cancer treatment did not reduce new breast cancer events. (2008) (4)
- The effect of 1-day multidisciplinary clinic on breast cancer treatment (2020) (4)
- Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer (2020) (4)
- Severe prolonged cholestatic hepatitis caused by exemestane (2010) (4)
- Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial. (2016) (4)
- Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. (2021) (4)
- Abstract 995: Transient low doses of DNA demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells (2012) (4)
- Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011) (2012) (3)
- TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer. (2018) (3)
- Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. (2010) (3)
- Déjà vu for breast cancer two? (2004) (3)
- A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases (2021) (3)
- The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote (2021) (3)
- Development of new brain metastases in triple negative breast cancer (2021) (3)
- One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy (2011) (3)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (3)
- Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (2018) (3)
- A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. (2016) (3)
- Preferences for Hypnotic Imagery for Hot-Flash Reduction: A Brief Communication (2010) (3)
- Treatment-emergent effects may predict benefit from endocrine therapy. (2013) (3)
- Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes (2012) (3)
- Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648) (2019) (3)
- Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms (2007) (3)
- A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy (2009) (3)
- Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. (2014) (3)
- The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures (2021) (3)
- Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity (2021) (3)
- Forecasting cancer: from precision to predictive medicine. (2021) (3)
- Erratum: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients (Journal of Clinical Pharmacology (2010) 50: 4 (450-458) DOI: 10.1177/0091270009359182) (2010) (3)
- Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy (2010) (3)
- Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. (2021) (3)
- PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions. (2018) (3)
- Abstract P3-12-02: Predictors of adherence to adjuvant endocrine therapy (ET) for early breast cancer (BC) in a prospective clinic-based cohort (2018) (2)
- Neoadjuvant Endocrine Therapy for Breast Cancer: An Overlooked Option? (2004) (2)
- Abstract P4-13-05: Safety results of the US expanded access program (EAP) of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) for whom letrozole therapy is deemed appropriate (2016) (2)
- Abstract P3-07-13: Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer (2016) (2)
- Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations? (2017) (2)
- Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers (2019) (2)
- Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
- Making it work: Breast cancer survivorship care at Johns Hopkins. (2012) (2)
- The role of pharmacogenetics in selection of breast cancer treatment (2009) (2)
- Complete Response to Single‐agent Palbociclib in Metastatic Breast Cancer: A Case Report (2017) (2)
- Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3. (2020) (2)
- Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial. (2013) (2)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). (2011) (2)
- Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome (2007) (2)
- A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. (2009) (2)
- Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib (2020) (2)
- Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis (2017) (2)
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. (2022) (2)
- Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation (2018) (2)
- Abstract P5-21-24: Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2– advanced breast cancer enrolled in an early access program (2018) (2)
- P1-12-20: The Safety and Tolerability of Vorinostat in Combination with Lapatinib in Advanced Solid Tumors. (2011) (2)
- Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial. (2006) (2)
- PD04-01: Predictors of Recovery of Ovarian Function during Aromatase Inhibitor (AI) Therapy. (2011) (2)
- Late effects in a high-risk population of breast cancer survivors (2021) (2)
- Predictors of non-receipt of first-line CDK 4/6 inhibitors (CDK4/6i) among patients with metastatic breast cancer (MBC). (2021) (2)
- P4-12-13: A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Interim Analysis. (2011) (2)
- Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer (2022) (2)
- Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials (2022) (2)
- The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention (2021) (2)
- Abstract P6-07-33: A clinicopathologic analysis of 45 patients with metaplastic breast cancer (2012) (2)
- Pharmacogenomics of Tamoxifen: Ready for Prime Time? (2010) (2)
- 964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) (2021) (1)
- A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women (2008) (1)
- Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML). (2010) (1)
- Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations. (2022) (1)
- Innovating and expanding weight loss strategies for breast cancer survivors (2021) (1)
- TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. (2014) (1)
- Adjuvant chemo endocrine therapy (2014) (1)
- Preoperative PARPi and irradiation (POPI) for women with an incomplete response to neoadjuvant chemotherapy (NAC) for breast cancer: A phase I trial. (2014) (1)
- Reply to H. Brauch et al. (2019) (1)
- Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner (2001) (1)
- 4–56 Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy (2007) (1)
- A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial. (2014) (1)
- Reply to K.I. Pritchard. (2013) (1)
- A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. (2010) (1)
- Comment on: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Authors' reply (2004) (1)
- Abstract PD10-08: Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121) (2012) (1)
- Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers (2019) (1)
- Association of Aromatase Inhibitor-Associated Musculoskeletal Symptoms with Ultrasonographic Changes at the Wrist. (2009) (1)
- Advances in the Adjuvant and Neoadjuvant Treatment of Breast Cancer (2007) (1)
- Extended adjuvant therapy for breast cancer--how much is enough? (2007) (1)
- Abstract P1-08-11: Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy (2013) (1)
- MR-image-based tissue analysis and its clinical applications (2002) (1)
- Sensitivity for detecting PIK3CA mutations in early-stage breast cancer with droplet digital PCR. (2013) (1)
- How many lesions to measure for response assessment? Comparing SULpeak changes in a single lesion and the sum of the 5 hottest lesions in 3 types of cancer and 3 types of therapy (2013) (1)
- ER‐alpha and ER‐beta genotypes predict tamoxifen effects on serum lipids in breast cancer patients (2004) (1)
- Assessing PERCIST 1.0 non-measurable (low FDG uptake) lesions in patients with breast cancer does not diminish the predictive value of FDG PET (2013) (1)
- Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial (2022) (1)
- Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. (2021) (1)
- Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs). (2016) (1)
- Abstract A15: Single-strand breaks in normal breast DNA are associated with measures of breast cancer risk, deficiencies in repair mechanisms, and diminished protection against oxidative processes (2012) (1)
- Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial (2006) (1)
- Assessing financial toxicity in patients with metastatic breast cancer: A single institution experience during the COVID-19 pandemic. (2021) (1)
- Abstract PS4-03: An automated DNA methylation assay for monitoring treatment response in patients with metastatic breast cancer (2021) (1)
- Effect of simvastatin on the pharmacokinetics of anastrozole. (2009) (1)
- Detection of Cancer Specific Mutations in Plasma of Early Stage Breast Cancer Patients (2013) (1)
- Reply to J.L. Blum et al and S. Lange et al. (2017) (1)
- Survivorship care plans: Recommended vs delivered care. (2017) (1)
- EDITORIAL DéjaVu for Breast Cancer Two (2004) (1)
- Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity (2021) (1)
- 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) (2022) (1)
- Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. (2011) (1)
- Abstract P3-04-08: Expression of hormone-responsive genes in benign breast tissue varies with menstrual cycle phase and menopausal status (2012) (1)
- Abstract PS5-25: Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms (2021) (0)
- Randomized, Double‐Blind Study of Controlled Release Paroxetine in Treatment of Menopausal Hot Flash (2003) (0)
- Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk (2006) (0)
- YIA22-007: Adaptive Nutrition and Exercise Weight loss (A-NEW) Study for Breast Cancer Survivors With Overweight or Obesity (2022) (0)
- Phase I/II trial of partial breast irradiation (PBI) with various concurrent chemotherapy regimens. (2012) (0)
- Behavioral and psychosocial quality improvement project in patients with early-stage breast cancer. (2022) (0)
- Reply to E. Hindié et al. (2019) (0)
- Abstract P3-07-62: Association of overexpression of hypoxia inducible factor 1α with response to neoadjuvant chemotherapy in early stage breast cancer (2016) (0)
- Abstract A136: Racial disparities in delayed initiation of adjuvant endocrine therapy among patients with breast cancer (2020) (0)
- Abstract CN13-03: Intraductal route of breast cancer prevention and therapy: from preclinical studies to Phase I trials (2008) (0)
- Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). (2012) (0)
- Postmenopausal hormone receptorpositive advanced breast cancer (2013) (0)
- Practice pattern treating older women with early stage breast cancer at Johns Hopkins. (2015) (0)
- Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 (2023) (0)
- Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA (2016) (0)
- Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms (2022) (0)
- Abstract P4-16-09: Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy (2019) (0)
- More choices, more questions: weighing the options for treating hot flashes. (2006) (0)
- Why is it so difficult to enroll patients in clinical trials (2014) (0)
- Abstract P6-12-21: Breast cancer survivors undergoing survivorship visits at Johns Hopkins are a high-risk population (2018) (0)
- Abstract PD10-07: Patient reported outcomes and early discontinuation of adjuvant endocrine therapy according to neighborhood poverty rate (2020) (0)
- Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer. (2022) (0)
- Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. (2020) (0)
- Abstract P5-12-05: CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (2016) (0)
- Abstract OT-13-08: A remote-directed “virtual” clinical trial in metastatic breast cancer to determine feasibility of evaluating patient response to immunotherapy using spliceosome mutational markers (SF3B1): The PRISMM trial (NCT04447651) (2021) (0)
- Abstract PD01-05: A Combination of HDAC Inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and Chemotherapy Drug(s) Causes Regression of Established Xenografts of Triple Negative Breast Cancer (2010) (0)
- Patient-reported outcomes and factors associated with early discontinuation of adjuvant endocrine therapy in premenopausal women with breast cancer (2018) (0)
- Commentary on “A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923” (2000) (0)
- Abstract P2-20-14: Relationship of HIF-1α and tumor infiltrating lymphocytes in patients with HER2-negative early-stage breast cancer treated with neoadjuvant chemotherapy (2023) (0)
- Abstract 5916: Weight loss intervention triggered gut microbiota modulation can positively impact obesity associated endocrine therapy resistance (2023) (0)
- Tamoxifen and raloxifene: Dealing with the side effects (2008) (0)
- Addressing the risk of infertility in young women with breast cancer (BC): A quality improvement (QI) intervention. (2017) (0)
- A phase I study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women with breast cancer. (2009) (0)
- Hypermethylated genes as biomarkers of breast cancer (2009) (0)
- A phase II study of weekly gemcitabine and docetaxel in first and second line metastatic breast cancer. (2016) (0)
- Adjuvant Endocrine Therapy (2018) (0)
- Change in tumor-to-liver uptake ratios is comparable to PERCIST 1.0 in predicting complete response in primary breast cancer systemic therapy (2013) (0)
- Making Strides in Adjuvant Therapy for Breast Cancer (2008) (0)
- Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk (2015) (0)
- Piloting survivorship care planning with the metastatic breast cancer patient. (2016) (0)
- Abstract PS9-58: Factors associated with sexual problems during adjuvant endocrine therapy (2021) (0)
- Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference (2017) (0)
- Abstract 1555: Single cell level treatment-specific characterization of HER2+ breast cancers treated with immune checkpoint inhibitors and entinostat (2020) (0)
- Abstract P6-10-05: TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer (2020) (0)
- Circulating extracellular domain of HER2 can be correlated with clinical response to chemotherapy in locally advanced breast cancer (2001) (0)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (0)
- Phase I/II Trial of Partial Breast Irradiation with Concurrent Dose-dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early-stage Breast Cancer: Late Assessment of Toxicity, Cosmetic Outcome, and Disease Recurrence (2011) (0)
- Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes (2008) (0)
- Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer. (2018) (0)
- T-DM1 adds to the armamentarium for targeting advanced HER2-positive breast cancer (2013) (0)
- Abstract P1-09-15: Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008 (2017) (0)
- Abstract P1-07-01: Characteristics, treatment and outcomes of breast cancer diagnosed during pregnancy and the year after delivery (2016) (0)
- Quality of life (QOL) changes in breast cancer patients participating in an anastrozole secondary prevention trial (2008) (0)
- Multinuclear and Multiparametric MR imaging as an early treatment response biomarker for preoperative systemic therapy in breast cancer : Preliminary Results (2008) (0)
- Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. (2022) (0)
- Development and Validation of a Method for Using Breast Core Needle Biopsies for Gene Expression Microarray Analyses 1 (2002) (0)
- Two Phase 1/2 Trials of Partial Breast Irradiation (PBI) With Concurrent Chemotherapy Regimens: Late Toxicity, Cosmetic Outcome, and Disease Recurrence (2014) (0)
- Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancer. (2006) (0)
- 767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
- Abstract P4-12-04: Association of single-strand breaks (SSBs) in normal breast DNA with estimates of breast cancer risk (2012) (0)
- Controversies in Treating Early HR-Positive Breast Cancer (2017) (0)
- Abstract PS2-14: Her2 expression in matched metastatic tumor and circulating tumor cells (ctcs) in breast cancer: Implications for profiling and monitoring of her2 status to help guide anti-her2 therapy (2021) (0)
- Outcomes from Two Phase I/II Trials of Partial-Breast Irradiation (PBI) and Concurrent Chemotherapy (2019) (0)
- Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer (2022) (0)
- 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
- Gene methylation and cytological atypia in random fine needle aspirates for assessment of breast cancer risk: 10-year follow up in average risk women. (2021) (0)
- How to Manage Complications of ADT (2018) (0)
- Pharmacogenetics of Aromatase Inhibitors: Present Understanding and Looking to the Future (2010) (0)
- Abstract P2-04-11: Promotion of immunogenicity using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer (2017) (0)
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022) (0)
- Abstract P6-10-07: Activating HER2 missense mutations in HER2-negative metastatic breast cancer (2020) (0)
- Abstract P5-13-09: Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes (2022) (0)
- Factors associated with weight gain during endocrine therapy for breast cancer. (2021) (0)
- A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases (2021) (0)
- Abstract A50: Soy isoflavones and vitamin D in breast cancer prevention. (2008) (0)
- Gene methylation in random FNA samples as biomarkers for breast cancer. (2012) (0)
- Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk (2022) (0)
- Study of Neurobehavioral Symptoms and Impairments in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor Therapy. (2009) (0)
- ASO Visual Abstract: The Impact of Radiotherapy Delay in Breast-Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures (2021) (0)
- Paroxetine reduced the frequency and severity of hot flushes in some postmenopausal women (2004) (0)
- CCR Co Per Aditya In t leagu polym used a cancer (0)
- Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow (2022) (0)
- Abstract P3-03-22: Overweight and obesity trends over 5 years in early stage and metastatic breast cancer patients (2023) (0)
- Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy. (2012) (0)
- Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer (2006) (0)
- Abstract 4088: Targeting glutamine metabolism in breast cancer (2011) (0)
- Abstract P5-04-06: Reprogramming the suppressive tumor microenvironment of breast cancer (2020) (0)
- Reply to A. Katz. (2019) (0)
- The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting (2022) (0)
- why do few cancer patients enrol into clinical trials (2018) (0)
- Increased African-American Enrollment in Breast Cancer Clinical Trials: A Single-Institution Experience (2014) (0)
- Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer (2022) (0)
- Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design (2017) (0)
- The impact of weight loss on physical function in overweight or obese breast cancer survivors. (2020) (0)
- ES1-3: Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease: Triple Negative Breast Cancer. (2011) (0)
- A randomized intervention involving family to improve communication in breast cancer care (2021) (0)
- MultiparametricMagnetic Resonance Imaging , Spectroscopy and Multinuclear ( 23 Na ) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2010) (0)
- Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy. (2015) (0)
- Piloting workshops to enhance hope among patients with advanced breast cancer and oncologists. (2019) (0)
- CYP genotypes influence the effect of tamoxifen therapy on serum lipids (2004) (0)
- Determinants of low cell yield in random fine needle aspiration (rFNA) procedures of the breast in healthy women unselected by risk. (2010) (0)
- Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (2010) (0)
- Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence (2012) (0)
- OT1-01-01: Prospective Clinical Trial Evaluating Efficacy of Zoledronic Acid (ZA) Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial. (2011) (0)
- Update on Epigenetic Agents in the Treatment of BC (2014) (0)
- Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission (2019) (0)
- Abstract P3-01-07: Phase II trial of palbociclib with fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor (2023) (0)
- Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition. (2020) (0)
- Abstract PS9-14: Feasibility of monitoring symptoms during endocrine therapy with patient reported outcomes collected via smart phone app (2021) (0)
- NeoadjuvantChemotherapyandShort-term MorbidityinPatientsUndergoingMastectomy WithandWithoutBreastReconstruction (2014) (0)
- Triple-negative breast cancer (TNBC) outcomes with partial breast irradiation and concurrent chemotherapy (PBI-CC) compared with whole breast irradiation and sequential chemotherapy (WBI-SC). (2011) (0)
- Abstract CS1-2: Searching for the optimal duration of adjuvant endocrine therapy in breast cancer (2018) (0)
- Abstract P4-14-01: POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer (2017) (0)
- Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes. (2009) (0)
- Abstract PD11-04: The impact of sleep on weight loss in overweight or obese breast cancer survivors (2021) (0)
- The Wong/Ellis article reviewed (2004) (0)
- Abstract 5167: Entinostat's modulation of myeloid derived suppressor cells through the STAT3-NFκB-AP-1 axis decreases suppressive signaling (2023) (0)
- A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing (2022) (0)
- Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk. (2006) (0)
- Obesity at diagnosis and after treatment in breast cancer survivors and risk of neuropathy. (2018) (0)
- Outcomes with External Beam Partial Breast Irradiation and Concurrent Chemotherapy (PBICC) Compared to Whole Breast Irradiation and Sequential Chemotherapy (WBISC) in Triple Negative Breast Cancer (TNBC) Patients (2011) (0)
- Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 (2023) (0)
- Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer (2008) (0)
- Abstract A22: Association of breast cancer risk and concentrations of tissue estrogens to single strand breaks in DNA (2017) (0)
- Patient-reported outcomes to assess symptoms in patients with metastatic breast cancer: Pilot implementation project. (2021) (0)
- Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy (2008) (0)
- Commentary (Brown/Stearns): Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Vered Stearns?
Vered Stearns is affiliated with the following schools:
